Overview

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and safety of a treatment regimen of 12 weeks or 8 weeks of simeprevir in combination with sofosbuvir in chronic hepatitis C virus (HCV) genotype 1 infected men and women without cirrhosis who are HCV treatment-naïve or treatment-experienced.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Infectious Diseases BVBA

Treatments:

Simeprevir
Sofosbuvir